Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000458545 | SCV000544512 | likely benign | Tuberous sclerosis 2 | 2024-11-22 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002257697 | SCV002531077 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-12-13 | criteria provided, single submitter | curation | |
Gene |
RCV002291628 | SCV002584119 | uncertain significance | not provided | 2022-10-13 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002257697 | SCV002740545 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-07-31 | criteria provided, single submitter | clinical testing | The p.E845G variant (also known as c.2534A>G), located in coding exon 21 of the TSC2 gene, results from an A to G substitution at nucleotide position 2534. The glutamic acid at codon 845 is replaced by glycine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV003463868 | SCV004206807 | uncertain significance | Isolated focal cortical dysplasia type II | 2023-10-09 | criteria provided, single submitter | clinical testing |